Compare KRUS & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRUS | SBFM |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.6M | 7.2M |
| IPO Year | 2019 | N/A |
| Metric | KRUS | SBFM |
|---|---|---|
| Price | $54.37 | $1.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $84.29 | $7.00 |
| AVG Volume (30 Days) | ★ 297.7K | 55.7K |
| Earning Date | 01-07-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $282,763,000.00 | $37,323,742.00 |
| Revenue This Year | $18.91 | $10.26 |
| Revenue Next Year | $20.16 | $32.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.88 | 13.24 |
| 52 Week Low | $40.03 | $1.16 |
| 52 Week High | $106.60 | $3.90 |
| Indicator | KRUS | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 35.84 |
| Support Level | $50.73 | $1.16 |
| Resistance Level | $56.62 | $1.40 |
| Average True Range (ATR) | 2.41 | 0.09 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 65.70 | 34.41 |
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.